In vitro Antifungal Activity of Ravuconazole Against Isolates of Dermatophytes and Candida Species from @entity1 with XXXX .

@entity1 @entity9202 @entity18203 @entity6313 @entity7409 @entity5132 @entity12736 @entity14476 @entity12734
The in vitro activity of ravuconazole (RVCZ) was compared with those of itraconazole (ITCZ) and terbinafine (TBF) against 73 dermatophyte isolates and 18 Candida spp. isolates recovered from @entity1 with @entity9202 at 4 dermatological clinics in Japan in 2011. The dermatophyte isolates consisted of @entity12734 (n=51), @entity12736 (n=20 : these strains were not identified by molecular phylogenetic analysis.), @entity12736 tonsurans (n=1), and @entity14476 (n=1). The Candida spp. isolates comprised @entity5132 (n=11), @entity7409 (n=5), @entity18203 (n=1), and C. pseudohaemulonii (n=1). RVCZ was highly active against all dermatophytes and all Candida spp. : the geometric mean (GM) MICs for @entity12734 and @entity12736 were 0.035  g/mL and MICs for T. tonsurans and @entity14476 were  <= 0.03 g/mL, and GM MICs for @entity5132 and @entity7409 were  <= 0.03 g/mL and MICs for @entity18203 and C. pseudohaemulonii were 0.25 and  <= 0.03 g/mL, respectively. Compared to RVCZ, ITCZ showed similar anti-dermatophytic and anti-Candida activities, while TBF had a slightly higher anti-dermatophytic but a markedly lower anti-Candida activity. These results suggest that RVCZ is a potential candidate systemic antifungal therapy against @entity6313 and other dermatomycoses that are refractory to topical antifungal therapy.
